Atopaxar

CAT: 0804-HY-18200-01Size: 1 mgDry Ice: NoHazardous: No
CAT#:0804-HY-18200-01Size:1 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Atopaxar (E5555) is a potent, orally active, selective and reversible thrombin receptor protease-activated receptor-1 (PAR-1) antagonist. Atopaxar, an antiplatelet agent, interferes with platelet signaling. Atopaxar can be used for the research of atherothrombotic disease[1][2].
CAS Number
[751475-53-3]
Product Name Alternative
E5555; ER-172594-00
UNSPSC
12352005
Target
Apoptosis; JAK; Protease Activated Receptor (PAR)
Type
Reference compound
Related Pathways
Apoptosis; Epigenetics; GPCR/G Protein; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Applications
Neuroscience-Neuromodulation
Field of Research
Cancer; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/atopaxar.html
Concentration
10mM
Purity
99.87
Solubility
DMSO : ≥ 100 mg/mL
Smiles
COC1=C(N2CCOCC2)C=C(C(CN(CC3=C4C(F)=C(OCC)C(OCC)=C3)C4=N)=O)C=C1C(C)(C)C
Molecular Formula
C29H38FN3O5
Molecular Weight
527.63
References & Citations
[1]Chris Dockendorff, et al. Discovery of 1,3-Diaminobenzenes as Selective Inhibitors of Platelet Activation at the PAR1 Receptor. ACS Med Chem Lett. 2012 Mar 8; 3 (3) : 232–237.|[2]Motoji Kogushi, et al. The novel and orally active thrombin receptor antagonist E5555 (Atopaxar) inhibits arterial thrombosis without affecting bleeding time in guinea pigs. Eur J Pharmacol. 2011 Apr 25;657 (1-3) :131-7.|[3]Sun J, et al., Discovery and evaluation of Atopaxar hydrobromide, a novel JAK1 and JAK2 inhibitor, selectively induces apoptosis of cancer cells with constitutively activated STAT3. Invest New Drugs. 2020 Aug;38 (4) :1003-1011.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
PAR1

Popular Products